Immune reactions in patients with bladder and prostatic cancer.
Although there are many reports of cellular immune reactions in bladder and prostatic carcinoma patients, few have demonstrated the presence of humoral reactivity. The use of microtechniques, especially the enzyme-linked immunosorbent assay (ELISA), has made sequential studies possible on patients with early or small tumours. Using this assay, the presence of serum antibodies has been demonstrated in both bladder and prostate patients, the specificities of these reactions being checked against a battery of different tumours and normal tissues. In many of the patients, with low or transient antibody levels, the presence of circulating immune complexes was shown by the Raji cell assay and analysed by double counter-current immunoelectrophoresis (DCIE). The content of these complexes appeared to be either antibody and tumour antigen or antibody and antiimmunoglobulin. In a small series of cryosurgically treated prostatic carcinoma patients, the course of these antibodies was monitored over several weeks, and the fluctuations in antibody levels were related to the presence of these different types of complexes.
D000912:Antibodies, Neoplasm / Q000032:analysis*; D000937:Antigen-Antibody Reactions; D002277:Carcinoma / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007158:Immunologic Techniques; D008297:Male; D009361:Neoplasm Invasiveness; D011471:Prostatic Neoplasms / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology*
D000912:Antibodies, Neoplasm